Skip to content

Independent register of U.S. FDA drug recalls · updated Oct 10, 2026

FDA Drug Recalls

207 recalls, newest first

Mar 16, 2023 Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-120-52 D-0552-2023

Mar 16, 2023 Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-383-52 D-0551-2023

Mar 16, 2023 Class II · Moderate risk

Doxazosin Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-109-52 D-0550-2023

Mar 16, 2023 Class II · Moderate risk

BusPIRone Hydrochloride Tablets USP

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-511-52 D-0549-2023

Mar 16, 2023 Class II · Moderate risk

Atorvastatin Calcium Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-946-52 D-0548-2023

Mar 13, 2023 Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0431-90 D-0486-2023

Mar 13, 2023 Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0446-30 D-0485-2023

Mar 13, 2023 Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0688-30 D-0484-2023

Mar 13, 2023 Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0710-90 D-0483-2023

Mar 13, 2023 Class II · Moderate risk

Glimepiride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0250-30 D-0482-2023

Mar 13, 2023 Class II · Moderate risk

Glimepiride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0488-30 D-0481-2023

Mar 13, 2023 Class II · Moderate risk

Glimepiride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0723-30 D-0480-2023

Mar 13, 2023 Class II · Moderate risk

Ropinirole

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 72189-0364-30 D-0479-2023

Mar 13, 2023 Class II · Moderate risk

Ropinirole

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 72189-0364-30 D-0478-2023

Mar 13, 2023 Class II · Moderate risk

Finasteride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0733-90 D-0477-2023

Mar 13, 2023 Class II · Moderate risk

Montelukast Sodium Tablets

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0009-30 D-0476-2023

Feb 24, 2023 Class II · Moderate risk

Unguentine Original Maximum Strength Pain Relieving/Antiseptic Ointment

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0452-2023

Feb 24, 2023 Class II · Moderate risk

Activator Concentrate

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0451-2023

Feb 24, 2023 Class II · Moderate risk

Nose Better Gel

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0450-2023

Feb 24, 2023 Class II · Moderate risk

Soltice Quick-RUB

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0449-2023

Feb 24, 2023 Class II · Moderate risk

Unguentine Original Ointment for Burns

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0448-2023

Feb 24, 2023 Class II · Moderate risk

Vencedor medicated balm

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0447-2023

Feb 24, 2023 Class II · Moderate risk

Alcolado Relampago

CGMP DEVIATIONS

Terminated cGMP deviation Ecometics, Inc. D-0446-2023

Feb 23, 2023 Class II · Moderate risk

Sterile Water for Injection

CGMP Deviations: Potential product carryover.

Terminated cGMP deviation Nephron Sc Inc NDC 0487-6105-01 D-0364-2023

Feb 21, 2023 Class II · Moderate risk

Phenylephrine HCl 20 mg

CGMP DEVIATIONS

Terminated cGMP deviation Denver Solutions, LLC DBA Leiters Health NDC 71449-148-94 D-0445-2023

Recalls by year

2026563
2025778
2024557
20231,122
20221,390
20211,152
2020930
20191,788
20181,681
20171,141
20161,199
20151,733
20141,309
20132,085
2012534
201134
20104
20072
20061